Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sangamo Therapeutics Inc

0.5899
-0.0078-1.31%
Volume:522.95K
Turnover:307.96K
Market Cap:140.16M
PE:-1.57
High:0.6014
Open:0.6000
Low:0.5800
Close:0.5977
Loading ...

Unusually active option classes on open July 24th

TIPRANKS
·
Yesterday

Sangamo Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
25 Jun

Sangamo Biosciences (SGMO) Receives a Buy from H.C. Wainwright

TIPRANKS
·
25 Jun

Sangamo Therapeutics Says Phase 1/2 Fabry Disease Study Showed Favorable Safety Profile; Shares Up Pre-Bell

MT Newswires Live
·
24 Jun

BRIEF-Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease

Reuters
·
24 Jun

Sangamo Therapeutics Receives Key FDA Designations and Advances Towards 2026 BLA Submission for Fabry Disease Gene Therapy

Reuters
·
24 Jun

Sangamo Therapeutics Inc. Conducted Annual Stockholders Meeting

Reuters
·
17 Jun

Sangamo Therapeutics Is Maintained at Overweight by Barclays

Dow Jones
·
14 May

Truist Financial Reaffirms Their Buy Rating on Sangamo Biosciences (SGMO)

TIPRANKS
·
14 May

Top Premarket Decliners

MT Newswires Live
·
13 May

Sangamo Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
13 May

BRIEF-Sangamo Therapeutics Q1 EPS USD -0.14 Vs. IBES Estimate USD -0.13

Reuters
·
13 May

Sangamo Therapeutics Reports Q1 2025 Net Loss of $30.6 Million, Down from $49.1 Million in 2024; EPS Improves to $0.14 Loss from $0.27

Reuters
·
13 May

Sangamo Therapeutics Launches $23 Million Share Offering with Warrants Priced at $0.50 Each

Reuters
·
13 May

Press Release: Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day

Dow Jones
·
13 May

Sangamo Therapeutics Delays Q1 2025 Earnings Call to Later Time on May 12

Reuters
·
13 May

Sangamo Therapeutics Inc expected to post a loss of 13 cents a share - Earnings Preview

Reuters
·
10 May

Press Release: Sangamo Therapeutics Announces First Quarter 2025 Earnings Call

Dow Jones
·
07 May

Sangamo Therapeutics Inc expected to post a loss of 13 cents a share - Earnings Preview

Reuters
·
05 May

Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Business Wire
·
29 Apr